van der Hem KG - Search Results

1

High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma.

Ossenkoppele GJ, Schuurhuis GJ, Jonkhoff AR, van der Hem KG, Legdeur MC, Boot-Bakker A, Westra AH, Dräger AM, Huijgens PC. Ossenkoppele GJ, et al. Among authors: van der hem kg. Eur J Cancer. 1996 Nov;32A(12):2058-63. doi: 10.1016/s0959-8049(96)00267-5. Eur J Cancer. 1996. PMID: 9014745 Clinical Trial.

2

All-trans retinoic acid toxicity.

van der Hem KG, Ossenkoppele GJ. van der Hem KG, et al. Eur J Haematol. 1992 Sep;49(3):148-9. doi: 10.1111/j.1600-0609.1992.tb00921.x. Eur J Haematol. 1992. PMID: 1446731 No abstract available.

3

The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.

van der Hem KG, Dräger AM, Huijgens PC, Tol C, Devillé W, Langenhuijsen MM. van der Hem KG, et al. Leukemia. 1994 Feb;8(2):266-73. Leukemia. 1994. PMID: 7508534

4

Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.

Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, Nauta JJ, van der Hem KG, Dräger AM, Langenhuijsen MM. Ossenkoppele GJ, et al. Among authors: van der hem kg. Bone Marrow Transplant. 1994 Jan;13(1):37-41. Bone Marrow Transplant. 1994. PMID: 7517255

5

Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.

van der Hem KG, Dräger AM, Odding JH, Huijgens PC. van der Hem KG, et al. Leuk Res. 1995 Sep;19(9):651-7. doi: 10.1016/0145-2126(95)00052-p. Leuk Res. 1995. PMID: 7564476

6

Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.

van der Hem KG, Dräger AM, Odding JH, Langenhuijsen MM, Huijgens PC. van der Hem KG, et al. Leuk Res. 1995 Jan;19(1):7-13. doi: 10.1016/0145-2126(94)00118-t. Leuk Res. 1995. PMID: 7837820

7

Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.

van der Hem KG, Schuurhuis GJ, Dräger AM, Odding JH, Huijgens PC. van der Hem KG, et al. Leuk Res. 1996 Sep;20(9):743-50. doi: 10.1016/0145-2126(96)00031-8. Leuk Res. 1996. PMID: 8947584

8

Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.

Dräger AM, van der Hem KG, Zevenbergen A, Odding JH, Huijgens PC, Schuurhuis GJ. Dräger AM, et al. Among authors: van der hem kg. Leukemia. 1999 Jan;13(1):62-9. doi: 10.1038/sj.leu.2401250. Leukemia. 1999. PMID: 10049062

9

Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors.

Thijsen SF, Schuurhuis GJ, van Oostveen JW, Theijsmeijer AP, van der Hem KG, Odding JH, Dräger AM, Ossenkoppele GJ. Thijsen SF, et al. Among authors: van oostveen jw, van der hem kg. Br J Cancer. 1999 Mar;79(9-10):1406-12. doi: 10.1038/sj.bjc.6690225. Br J Cancer. 1999. PMID: 10188883 Free PMC article.

10

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

Doorduijn JK, van der Holt B, van Imhoff GW, van der Hem KG, Kramer MH, van Oers MH, Ossenkoppele GJ, Schaafsma MR, Verdonck LF, Verhoef GE, Steijaert MM, Buijt I, Uyl-de Groot CA, van Agthoven M, Mulder AH, Sonneveld P. Doorduijn JK, et al. Among authors: van der hem kg. J Clin Oncol. 2003 Aug 15;21(16):3041-50. doi: 10.1200/JCO.2003.01.076. J Clin Oncol. 2003. PMID: 12915593 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

27 results

Search Page